Literature DB >> 34160571

Progress in Pharmacotherapy for Obesity.

Susan Z Yanovski1, Jack A Yanovski2.   

Abstract

Entities:  

Year:  2021        PMID： 34160571      PMCID： PMC8277731          DOI： 10.1001/jama.2021.9486

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  10 in total

1.  Naltrexone extended-release plus bupropion extended-release for treatment of obesity.

Authors:  Susan Z Yanovski; Jack A Yanovski
Journal:  JAMA       Date:  2015 Mar 24-31       Impact factor: 56.272

2.  Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

Authors:  Melanie Davies; Louise Færch; Ole K Jeppesen; Arash Pakseresht; Sue D Pedersen; Leigh Perreault; Julio Rosenstock; Iichiro Shimomura; Adie Viljoen; Thomas A Wadden; Ildiko Lingvay
Journal:  Lancet       Date:  2021-03-02       Impact factor: 79.321

3.  Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.

Authors:  Thomas A Wadden; Timothy S Bailey; Liana K Billings; Melanie Davies; Juan P Frias; Anna Koroleva; Ildiko Lingvay; Patrick M O'Neil; Domenica M Rubino; Dorthe Skovgaard; Signe O R Wallenstein; W Timothy Garvey
Journal:  JAMA       Date:  2021-04-13       Impact factor: 56.272

Review 4.  Long-term drug treatment for obesity: a systematic and clinical review.

Authors:  Susan Z Yanovski; Jack A Yanovski
Journal:  JAMA       Date:  2014-01-01       Impact factor: 56.272

Review 5.  Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.

Authors:  Rohan Khera; Mohammad Hassan Murad; Apoorva K Chandar; Parambir S Dulai; Zhen Wang; Larry J Prokop; Rohit Loomba; Michael Camilleri; Siddharth Singh
Journal:  JAMA       Date:  2016-06-14       Impact factor: 56.272

6.  Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

Authors:  Domenica Rubino; Niclas Abrahamsson; Melanie Davies; Dan Hesse; Frank L Greenway; Camilla Jensen; Ildiko Lingvay; Ofri Mosenzon; Julio Rosenstock; Miguel A Rubio; Gottfried Rudofsky; Sayeh Tadayon; Thomas A Wadden; Dror Dicker
Journal:  JAMA       Date:  2021-04-13       Impact factor: 56.272

7.  Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Authors:  John P H Wilding; Rachel L Batterham; Salvatore Calanna; Melanie Davies; Luc F Van Gaal; Ildiko Lingvay; Barbara M McGowan; Julio Rosenstock; Marie T D Tran; Thomas A Wadden; Sean Wharton; Koutaro Yokote; Niels Zeuthen; Robert F Kushner
Journal:  N Engl J Med       Date:  2021-02-10       Impact factor: 91.245

8.  Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.

Authors:  W Timothy Garvey; Andreas L Birkenfeld; Dror Dicker; Geltrude Mingrone; Sue D Pedersen; Altynai Satylganova; Dorthe Skovgaard; Danny Sugimoto; Camilla Jensen; Ofri Mosenzon
Journal:  Diabetes Care       Date:  2020-03-05       Impact factor: 19.112

Review 9.  The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.

Authors:  Thinzar Min; Stephen C Bain
Journal:  Diabetes Ther       Date:  2020-12-15       Impact factor: 2.945

10.  A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.

Authors:  Aaron S Kelly; Pernille Auerbach; Margarita Barrientos-Perez; Inge Gies; Paula M Hale; Claude Marcus; Lucy D Mastrandrea; Nandana Prabhu; Silva Arslanian
Journal:  N Engl J Med       Date:  2020-03-31       Impact factor: 91.245
  10 in total
  9 in total

Review 1.  Cardiovascular Disease Risk Reduction and Body Mass Index.

Authors:  Rohan Samson; Pierre Vladimir Ennezat; Thierry H Le Jemtel; Suzanne Oparil
Journal:  Curr Hypertens Rep       Date:  2022-07-05       Impact factor: 4.592

2.  Effects of Heterozygous Variants in the Leptin-Melanocortin Pathway on Roux-en-Y Gastric Bypass Outcomes: a 15-Year Case-Control Study.

Authors:  Alejandro Campos; Lizeth Cifuentes; Anas Hashem; Bradley Busebee; Maria D Hurtado-Andrade; Maria L Ricardo-Silgado; Alison McRae; Alan De la Rosa; Fauzi Feris; Joshua T Bublitz; Donald Hensrud; Michael Camilleri; Todd A Kellogg; Jeanette E Eckel-Passow; Janet Olson; Andres Acosta
Journal:  Obes Surg       Date:  2022-06-03       Impact factor: 3.479

Review 3.  Integrated Care Model of Adiposity-Related Chronic Diseases.

Authors:  Thierry H Le Jemtel; Rohan Samson; Suzanne Oparil
Journal:  Curr Hypertens Rep       Date:  2022-09-09       Impact factor: 4.592

4.  Use of prescription medications associated with weight gain among US adults, 1999-2018: A nationally representative survey.

Authors:  Craig M Hales; Qiuping Gu; Cynthia L Ogden; Susan Z Yanovski
Journal:  Obesity (Silver Spring)       Date:  2021-12-14       Impact factor: 9.298

5.  Assessing the use of prescription drugs and dietary supplements in obese respondents in the National Health and Nutrition Examination Survey.

Authors:  Laura A Barrett; Aiwen Xing; Julia Sheffler; Elizabeth Steidley; Terrence J Adam; Rui Zhang; Zhe He
Journal:  PLoS One       Date:  2022-06-03       Impact factor: 3.752

Review 6.  Nutritional Management in Bariatric Surgery Patients.

Authors:  Andrea Deledda; Stefano Pintus; Andrea Loviselli; Michele Fosci; Giovanni Fantola; Fernanda Velluzzi
Journal:  Int J Environ Res Public Health       Date:  2021-11-17       Impact factor: 3.390

7.  Hua-Tan-Sheng-Jing Decoction Treats Obesity With Oligoasthenozoospermia by Up-Regulating the PI3K-AKT and Down-Regulating the JNK MAPK Signaling Pathways: At the Crossroad of Obesity and Oligoasthenozoospermia.

Authors:  Yang Dong; Yanfei Zheng; Linghui Zhu; Tianxing Li; Yuanyuan Guan; Shipeng Zhao; Qi Wang; Ji Wang; Lingru Li
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

Review 8.  Obesity and Endothelial Function.

Authors:  Masato Kajikawa; Yukihito Higashi
Journal:  Biomedicines       Date:  2022-07-19

9.  Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity.

Authors:  Wissam Ghusn; Alan De la Rosa; Daniel Sacoto; Lizeth Cifuentes; Alejandro Campos; Fauzi Feris; Maria Daniela Hurtado; Andres Acosta
Journal:  JAMA Netw Open       Date:  2022-09-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.